Peer-influenced content. Sources you trust. No registration required. This is HCN.
JAMA Network
In this double-blind randomized clinical trial with 93 participants, the percentage of heavy drinking days during 32 weeks of follow-up was significantly lower in the psilocybin group than in the diphenhydramine group and was accompanied by a decrease in daily alcohol consumption.
Psychiatry September 6th 2022
Psych Congress Network
In what is thought to be the largest study to date of any type of ketamine treatment, the findings revealed that, after four sessions, 89 percent of participants reported improvement in their depression and/or anxiety symptoms. On the PHQ-9 or GAD-7 scale, 63 percent of participants saw a 50% or greater improvement. PHQ-9 remission rates were 32.6 percent and GAD-7 remission rates were 31.3 percent. Furthermore, at the end of the four weeks, 62 percent of patients who had suicidal ideation prior to treatment reported no suicidal ideation.
Psychiatry August 8th 2022
MDLinx
Researchers studied the effects of four repeated low doses of LSD, administered under lab conditions every three to four days, using approximately 1/8th the dose typically used to “trip” on LSD.
Drug Policy Alliance
Here’s everything you could possibly want to know about “magic” mushrooms, including their short- and long-term effects on people, risks, history, and much more.
Clinical Pharmacology August 5th 2022